Drugs / HRIG
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT07342257 Comparator | Nov 2024 → May 2025 | rabies | Synermore Biologics (Suzhou) Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRIG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07342257 ↗ |
| Modality | Protein / enzyme biologic | “Human Rabies Immunoglobulin” NCT07342257 ↗ |
| Route | Intramuscular | “HRIG should be administered intramuscularly” NCT07342257 ↗ |